About Erasca, Inc.
https://www.erasca.comErasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
CEO
Jonathan E. Lim
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 86
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
Goldman Sachs
Buy
Mizuho
Outperform
Morgan Stanley
Equal Weight
B of A Securities
Underperform
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:22.73M
Value:$188.88M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:20.23M
Value:$168.13M
VR ADVISER, LLC
Shares:17.86M
Value:$148.39M
Summary
Showing Top 3 of 158
About Erasca, Inc.
https://www.erasca.comErasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $34.55M ▼ | $-30.61M ▲ | 0% | $-0.11 ▲ | $-29.86M ▼ |
| Q2-2025 | $0 | $38.13M ▲ | $-33.88M ▼ | 0% | $-0.12 ▼ | $-29.84M ▲ |
| Q1-2025 | $0 | $35.63M ▲ | $-30.97M ▲ | 0% | $-0.11 | $-34.81M ▼ |
| Q4-2024 | $0 | $34.88M ▼ | $-32.23M ▼ | 0% | $-0.11 | $-31.4M ▲ |
| Q3-2024 | $0 | $37.24M | $-31.2M | 0% | $-0.11 | $-36.4M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $288.4M ▼ | $420.4M ▼ | $72.52M ▼ | $347.89M ▼ |
| Q2-2025 | $300.66M ▼ | $445.39M ▼ | $73.13M ▲ | $372.26M ▼ |
| Q1-2025 | $304.58M ▲ | $471.24M ▼ | $71.74M ▼ | $399.5M ▼ |
| Q4-2024 | $298.31M ▼ | $502.53M ▼ | $79.03M ▲ | $423.5M ▼ |
| Q3-2024 | $318.91M | $528.9M | $78.85M | $450.04M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-30.61M ▲ | $-21.66M ▼ | $25.7M ▲ | $41K ▼ | $4.09M ▲ | $-21.66M ▼ |
| Q2-2025 | $-33.88M ▼ | $-20.53M ▲ | $15.74M ▼ | $447K ▲ | $-4.34M ▼ | $-20.56M ▲ |
| Q1-2025 | $-30.97M ▲ | $-31.55M ▼ | $34.27M ▲ | $33K ▼ | $2.74M ▲ | $-31.64M ▼ |
| Q4-2024 | $-32.23M ▼ | $-24.56M ▼ | $22.62M ▲ | $801K ▼ | $-1.15M ▲ | $-24.56M ▼ |
| Q3-2024 | $-31.2M | $-22.42M | $-102.59M | $21.1M | $-103.92M | $-22.42M |
CEO
Jonathan E. Lim
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 86
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
Goldman Sachs
Buy
Mizuho
Outperform
Morgan Stanley
Equal Weight
B of A Securities
Underperform
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:22.73M
Value:$188.88M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:20.23M
Value:$168.13M
VR ADVISER, LLC
Shares:17.86M
Value:$148.39M
Summary
Showing Top 3 of 158